Vor Biopharma Inc. (NYSE:VOR) Receives $11.36 Consensus Target Price from Analysts

Shares of Vor Biopharma Inc. (NYSE:VOR) have been assigned a consensus recommendation of “Buy” from the seven brokerages that are presently covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $11.36.

Several equities research analysts have issued reports on the company. Robert W. Baird cut their target price on Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. HC Wainwright reaffirmed a “buy” rating and issued a $17.50 target price on shares of Vor Biopharma in a research report on Tuesday, December 10th. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Vor Biopharma in a research note on Monday, December 9th. Finally, JMP Securities reissued a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th.

Vor Biopharma Trading Down 6.0 %

Vor Biopharma stock opened at $1.41 on Wednesday. The stock has a market cap of $96.82 million, a P/E ratio of -0.85 and a beta of -0.45. The company has a 50-day moving average price of $1.21 and a 200 day moving average price of $0.97. Vor Biopharma has a 12-month low of $0.63 and a 12-month high of $2.43.

Vor Biopharma (NYSE:VOR) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.40). As a group, analysts forecast that Vor Biopharma will post -1.42 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC acquired a new stake in Vor Biopharma during the 2nd quarter worth approximately $53,000. Exchange Traded Concepts LLC boosted its holdings in Vor Biopharma by 40.8% in the third quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock valued at $116,000 after purchasing an additional 48,017 shares during the period. Renaissance Technologies LLC grew its stake in Vor Biopharma by 48.0% during the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock worth $495,000 after purchasing an additional 160,642 shares in the last quarter. Finally, Rosalind Advisors Inc. purchased a new stake in Vor Biopharma during the 3rd quarter worth about $54,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.